The results provide a basis for developing JAK1/JAK2-targeted treatments for eosinophilic cellulitis and other eosinophilic diseases, the researchers conclude.
These new findings suggest the need for expansion of JAK1/JAK2 targeting approaches for treatment of eosinophilic cellulitis and other types of eosinophilic disease.